RPR Gencell reshuffles its cards

Rhone-Poulenc Rorer Inc. is using the flexibility of its RPR Gencell division to reshuffle its gene therapy bets, de-emphasizing ex vivo therapy and bringing in more of the latest in genomics and other drug discovery technologies.

The latest move is a research agreement with Stanford University, worth up to $5 million, under which university scientists will be able to apply for research grants in gene therapy and drug discovery. ...